[en] This position paper of the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) addresses the rationale for separate diagnostic and intervention thresholds in osteoporosis. We conclude that the current BMD-based diagnostic criteria for osteoporosis be retained whilst clarity is brought to bear on the distinction between diagnostic and intervention thresholds.
Disciplines :
General & internal medicine Public health, health care sciences & services
Author, co-author :
Kanis, John A ; Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK. w.j.pontefract@sheff.ac.uk ; Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia. w.j.pontefract@sheff.ac.uk
McCloskey, Eugene V; Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK ; Centre for Integrated Research in Musculoskeletal Ageing (CIMA), Mellanby Centre for Musculoskeletal Research, University of Sheffield, Sheffield, UK
Harvey, Nicholas C; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, SO16 6YD, UK ; NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, UK
Cooper, Cyrus; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, SO16 6YD, UK ; NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, UK ; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
Rizzoli, Rene; Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, 1211, Geneva 14, Switzerland
Dawson-Hughes, Bess; Jean Mayer USDA Human Nutrition Research Center On Aging, Tufts University, Boston, MA, USA
Maggi, Stefania; Institute of Neuroscience, Aging Branch, CNR, Padua, Italy
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique ; WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging, Liege, Belgium
Language :
English
Title :
The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis.
Publication date :
25 October 2022
Journal title :
Osteoporosis International
ISSN :
0937-941X
eISSN :
1433-2965
Publisher :
Springer Science and Business Media Deutschland GmbH, England
The conceptual description of osteoporosis dates back nearly 30 years arising from an international consensus conference held in Hong Kong in March 1993, sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the European Foundation for Osteoporosis and Bone Disease (now the International Osteoporosis Foundation) and the American National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) []. Osteoporosis was described as: ‘A systemic skeletal disease characterised by low bone mass and micro-architectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture’, a conceptual definition supported several years later by the NIH Consensus Development Panel on Osteoporosis [].
Harvey NCW, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster J-Y, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int 28:1507–1529 DOI: 10.1007/s00198-016-3894-y
McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E, Hadji P, Payer J, Palmer K, Stad R, O’Kelly J, Papapoulos S (2021) The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int 32(2):251–259 DOI: 10.1007/s00198-020-05557-z
Skjødt MK, Ernst MT, Khalid S, Libanati C, Cooper C, Delmestri A, Rubin KH, Javaid MK, Martinez-Laguna D, Toth E, Prieto-Alhambra D, Abrahamsen B (2021) The treatment gap after major osteoporotic fractures in Denmark 2005–2014: a combined analysis including both prescription-based and hospital-administered anti-osteoporosis medications. Osteoporos Int 32(10):1961–1971 DOI: 10.1007/s00198-021-05890-x
Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int 25:1439–1443 DOI: 10.1007/s00198-014-2655-z
Paskins Z, Ong T, Armstrong DJ (2020) Bringing osteoporosis up to date: time to address the identity crisis. Age Ageing 49:329–331 DOI: 10.1093/ageing/afaa022
Anonymous (1993) Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646–650
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–95
World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group WHO Technical Report Series 843. World Health Organization, Geneva
Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141 DOI: 10.1002/jbmr.5650090802
Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ III, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467–475 DOI: 10.1016/j.bone.2007.11.001
Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–489 DOI: 10.1007/s001980050093
Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM, International Society for Clinical Densitometry (2006) Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 9:4–14 DOI: 10.1016/j.jocd.2006.05.002
Kanis JA, Glüer CC, for the Committee of Scientific Advisors, International Osteoporosis Foundation (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11:192–202 DOI: 10.1007/s001980050281
Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, Delmas P, Eisman J, Johnell O, Jonsson B, Melton L, Oden A, Papapoulos S, Pols H, Rizzoli R, Silman A, Tenenhouse A, International Osteoporosis Foundation, National Osteoporosis Foundation (2002) A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13:527–536 DOI: 10.1007/s001980200069
DeLaet CEDH, Van Hout BA, Burger H, Hofman A, Weel AEAM, Pols HAP (1998) Hip fracture prediction in elderly men and women: validation in the Rotterdam Study. J Bone Miner Res 13:1587–1593 DOI: 10.1359/jbmr.1998.13.10.1587
Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ III, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194 DOI: 10.1359/JBMR.050304
Langsetmo L, Leslie WD, Zhou W, Goltzman D, Kovacs CS, Prior J (2010) Using the same bone density reference database for men and women provides a simpler estimation of fracture risk. J Bone Miner Res 25:2108–2114 DOI: 10.1002/jbmr.112
Riggs LB, Melton LJ (eds) (1995) Osteoporosis: etiology, diagnosis, and management, 2nd edn. Lippincott-Raven Publishers, Philadelphia
World Health Organization (2003) Prevention and management of osteoporosis: report of a WHO scientific group. WHO Technical Report Series, 921. World Health Organization, Geneva
Food and Drug Administration (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products, Food and Drug Administration, Rockville, MD
Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2. London, CHMP. Nov 2006
Reginster JY, Abadie E, Delmas P, Rizzoli R, Dere W, der Auwera P, Avouac B, Brandi ML, Daifotis A, Diez-Perez A, Calvo G, Johnell O, Kaufman JM, Kreutz G, Laslop A, Lekkerkerker F, Mitlak B, Nilsson P, Orloff J, Smillie M, Taylor A, Tsouderos Y, Ethgen D, Flamion B (2006) Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos Int 17:1–7 DOI: 10.1007/s00198-005-1984-3
Pharmaceuticals and Medical Devices Agency, Japan Ministry of Health (2022). https://ss.pmda.go.jp/en_all/search.x?q=osteoporosis&ie=utf8&cat=0&pagemax=10&imgsize=1&pdf=ok&zoom=1&suggest=1&counsel=1&ref=www.pmda.go.jp&pid=Fp8oj1XtsOnvzmF1SMqOwQ.&qid=YlyMtLtewUXjdTr9eaLGkxC7j2s5IqGL&page=2 Accessed June 16 2022
World Health Organization (1998) Guidelines for preclinical evaluation and clinical trials in osteoporosis. WHO, Geneva
Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgström F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82. 10.1007/s11657-020-00871-9 DOI: 10.1007/s11657-020-00871-9
Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. 10.1007/s11657-013-0136-1 DOI: 10.1007/s11657-013-0136-1
Willers C, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Borgström F, Kanis JA, and the SCOPE review panel of the IOF (2022) Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos 17:23. 10.1007/s11657-021-00969-8 DOI: 10.1007/s11657-021-00969-8
Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV, and The Advisory Board of the National Osteoporosis Guideline Group (2016) A systematic review of intervention thresholds based on FRAX A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25. 10.1007/s11657-016-0278-z DOI: 10.1007/s11657-016-0278-z
Fuggle NR, Curtis B, Clynes M, Zhang J, Ward K, Javaid MK, Harvey NC, Dennison E, Cooper C (2021) The treatment gap: the missed opportunities for osteoporosis therapy. Bone 144:115833. 10.1016/j.bone.2020.115833 DOI: 10.1016/j.bone.2020.115833
McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E, Hadji P, Payer J, Palmer K, Stad R, O’Kelly J, Papapoulos S (2022) Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe. Arch Osteoporos 17(1):20. 10.1007/s11657-021-01048-8 DOI: 10.1007/s11657-021-01048-8
Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C, Cooper and International Osteoporosis Foundation Working Group (2013) Capture the Fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24(8):2135–2152 DOI: 10.1007/s00198-013-2348-z
Javaid MK, Kyer C, Mitchell PJ, Chana J, Moss C, Edwards MH, McLellan AR, Stenmark J, Pierroz DD, Schneider MC, Kanis JA, Akesson K, Cooper C, IOF Fracture Working Group, EXCO (2015) Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture(R) Best Practice Framework tool. Osteoporos Int 26:2573–2578 DOI: 10.1007/s00198-015-3192-0
Mitchell PJ, Cooper C, Fujita M, Halbout P, Åkesson K, Costa M, Dreinhöfer KE, Marsh DR, Lee JK, Chan DD, Javaid MK (2019) Quality improvement initiatives in fragility fracture care and prevention. Curr Osteoporos Rep 17(6):510–520 DOI: 10.1007/s11914-019-00544-8
Beaupre LA, Moradi F, Khong H, Smith C, Evens L, Hanson HM, Juby AG, Kivi P, Majumdar SR, STOP-Fracture Team (2020) Implementation of an in-patient hip fracture liaison services to improve initiation of osteoporosis medication use within 1-year of hip fracture: a population-based time series analysis using the RE-AIM framework. Arch Osteoporos 15(1):83. 10.1007/s11657-020-00751-2 DOI: 10.1007/s11657-020-00751-2
Barton DW, Piple AS, Smith CT, Moskal SA, Carmouche JJ (2021) The Clinical impact of fracture liaison services: a systematic review. Geriatr Orthop Surg Rehabil 12:2151459320979978 DOI: 10.1177/2151459320979978
Fuggle NR, Javaid MK, Fujita M, Halbout P, Dawson-Hughes B, Rizzoli R, Reginster JY, Kanis JA, Cooper C (2020) Fracture risk assessment and how to implement a fracture liaison service. In: Falaschi P, Marsh D (eds) Orthogeriatrics: the management of older patients with fragility fractures [Internet]. Chapter 14. Springer; 2021, Cham (CH)
Li N, Hiligsmann M, Boonen A, van Oostwaard MM, de Bot RTAL, Wyers CE, Bours SPG, van den Bergh JP (2021) The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis. Osteoporos Int 32:1517–1530 DOI: 10.1007/s00198-021-05911-9
Naranjo A, Prieto-Alhambra D, Sánchez-Martín J, Pérez-Mitru A, Brosa M (2022) Cost-effectiveness analysis of fracture liaison services compared with standard of care in the secondary prevention of fragility fractures in Spain. Clinicoecon Outcomes Res 14:249–264 DOI: 10.2147/CEOR.S350790
Cranney A, Jamal SA, Tsang JF, Josse RG, Leslie WD (2007) Low bone mineral density and fracture burden in postmenopausal women. CMAJ 177:575–580 DOI: 10.1503/cmaj.070234
Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120–127 DOI: 10.1007/PL00004173
Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Prediction of fracture from low bone mineral density measurements overestimates risk. Bone 26:387–391 DOI: 10.1016/S8756-3282(00)00238-6
Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, Hochberg MC, Vogt MT, Orwoll ES, Study of Osteoporotic Fractures Research Group (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90:2787–2793 DOI: 10.1210/jc.2004-1568
Oden A, McCloskey EV, Johansson H, Kanis JA (2013) Assessing the impact of osteoporosis on the burden of hip fractures. Calcif Tissue Int 92:42–49 DOI: 10.1007/s00223-012-9666-6
Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten-year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995 DOI: 10.1007/s001980170006
Hui SL, Slemenda CW, Johnston CC Jr (1988) Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804–1809 DOI: 10.1172/JCI113523
Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl D, Cyrus Cooper C, on behalf of the IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239–2256 DOI: 10.1007/s00198-012-1964-3
The Asia-Pacific regional audit (2013) Epidemiology, costs & burden of osteoporosis in 2013. https://www.osteoporosis.foundation/sites/iofbonehealth/files/2019-06/2013_Asia_Pacific_Audit_English.pdf (accessed 12th June 2022)
Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX® with and without bone mineral density. Calcif Tiss Int 90:1–13 DOI: 10.1007/s00223-011-9544-7
McCloskey E (2016) A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base. Osteoporos Int 27:417–419 DOI: 10.1007/s00198-015-3406-5
Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD (2018) Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 379(25):2407–2416. 10.1056/NEJMoa1808082 DOI: 10.1056/NEJMoa1808082
McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A, Orgee J, Ashford R, Forster M, Cliffe J, Kersh L, Brazier J, Nichol J, Aropuu S, Jalava T, Kanis JA (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22:135–141 DOI: 10.1359/jbmr.061008
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333 DOI: 10.1001/jama.288.3.321
Li Y, Wei FF, Thijs L, Boggia J, Asayama K, Hansen TW, Kikuya M, Björklund-Bodegård K, Ohkubo T, Jeppesen J, Gu YM, Torp-Pedersen C, Dolan E, Liu YP, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Mena L, Maestre GE, Filipovský J, Imai Y, O’Brien E, Wang JG, Staessen JA, International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO) Investigators (2014) Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation 130:466–74 DOI: 10.1161/CIRCULATIONAHA.113.004876
Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–1444 DOI: 10.1007/s00198-008-0588-0
Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 339:b4229 DOI: 10.1136/bmj.b4229
Hippisley-Cox J, Coupland C, Brindle P (2017) Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 357:j2099 DOI: 10.1136/bmj.j2099
Kanis JA, McCloskey E, Branco J, Brandi ML, Dennison E, Devogelaer JP, Ferrari S, Kaufman JM, Papapoulos S, Reginster JY, Rizzoli R (2014) Goal-directed treatment of osteoporosis in Europe. Osteoporos Int 25:2533–2543 DOI: 10.1007/s00198-014-2787-1
Kanis JA, Johansson H, Harvey NC, McCloskey EV (2018) A brief history of FRAX. Arch Osteoporos 13:118. 10.1007/s11657-018-0510-0 DOI: 10.1007/s11657-018-0510-0
Kanis JA, Harvey NC, Johansson H, Liu E, Lorentzon M, Leslie WD, Eugene V, McCloskey E (2020) A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res 33:187–196 DOI: 10.1007/s40520-019-01432-y
Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV, and the Epidemiology and Quality of Life Working Group of IOF (2013) Worldwide uptake of FRAX. Arch Osteoporos 8:166. 10.1007/s11657-013-0166-8 DOI: 10.1007/s11657-013-0166-8
Kanis JA, Odén A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23:423–431 DOI: 10.1007/s00198-011-1846-0
Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hodsman AB, Jamal AS, Josse RG, Kaiser SM, Kvern B, Morin S, Siminoski K, Scientific Advisory Council of Osteoporosis Canada (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–73 DOI: 10.1503/cmaj.100771
Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, Harvey N, Kanis J, Leyland S, Low R, McCloskey E, Moss K, Parker J, Paskins Z, Poole K, Reid DM, Stone M, Thomson J, Vine N, Compston J (2022) Correction: UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17(1):80. 10.1007/s11657-022-01115-8 (Erratumfor:ArchOsteoporos.2022Apr5;17(1):58) DOI: 10.1007/s11657-022-01115-8
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM (2014) Tanner B Randall S, Lindsay R (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381 DOI: 10.1007/s00198-014-2794-2
Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis–executive summary. Arch Osteoporos 7:3–20. 10.1007/s11657-012-0109-9 DOI: 10.1007/s11657-012-0109-9
Kanis JA, Cooper C, Rizzoli R, Reginster J-Y; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44
Kanis JA, Johansson H, Harvey NC, McCloskey EV, Lorentzon M, Liu E, Vandenput L, McCloskey EV, National Osteoporosis Guideline Group (2021) An assessment of intervention thresholds for very high risk applied to the NOGG guidelines. A report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int 32:1951–1960 DOI: 10.1007/s00198-021-05942-2
Axelsson KF, Johansson H, Lundh D, Möller M, Lorentzon M (2020) Association between recurrent fracture risk and implementation of fracture liaison services in four Swedish hospitals: a cohort study. J Bone Miner Res 35:1216–1223 DOI: 10.1002/jbmr.3990
Wu CH, Tu ST, Chang YF, Chan DC, Chien JT, Lin CH, Singh S, Dasari M, Chen JF, Tsai KS (2018) Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. Bone 111:92–100 DOI: 10.1016/j.bone.2018.03.018
Kanis JA on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield UK. http://www.shef.ac.uk/FRAX/index.htm . accessed 24 Sept 2022
Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ 3rd, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046 DOI: 10.1007/s00198-007-0343-y
Marques A, Ferreira RJ, Santos E, Loza E, Carmona L, da Silva JA (2015) The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis 74(11):1958–1967 DOI: 10.1136/annrheumdis-2015-207907
Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV, and the Epidemiology and Quality of Life Working Group of IOF (2013) Worldwide uptake of FRAX. Arch Osteoporos 8:166. 10.1007/s11657-013-0166-8 DOI: 10.1007/s11657-013-0166-8
National Institute for Health and Care Excellence (2012) NICE clinical guideline 146. Osteoporosis: assessing the risk of fragility fracture. London, UK. https://www.nice.org.uk/guidance/cg146, Accessed 2 June 2022
Socialstyrelsen (2010) Nationella riktlinjer för rörelseorganens sjukdomar 2010 - stöd för styrning och ledning. Preliminär version. http://docplayer.se/14004700-Nationella-riktlinjer-for-rorelseorganens-sjukdomar-2010-stod-for-styrning-och-ledning-preliminar-version-inaktuellt.html. Accessed 20 Sept 2019
Kanis JA, Johansson H, Odén A, McCloskey EV (2012) The distribution of FRAX® based probabilities in women from Japan. J Bone Miner Metab 30:700–705 DOI: 10.1007/s00774-012-0371-3
Kanis JA, Johnell O, Oden A, Johansson H, McCloskey EV (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397 DOI: 10.1007/s00198-007-0543-5
Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408 DOI: 10.1007/s00198-008-0712-1
Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M, and G. National Osteoporosis Guideline (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108 DOI: 10.1016/j.maturitas.2008.11.022
Clark P, Denova-Gutiérrez E, Zerbini C, Sanchez A, Messina O, Jaller JJ, Campusano C, Orces CH, Riera G, Johansson H, Kanis JA (2018) FRAX-based intervention and assessment thresholds in seven Latin American countries. Osteoporos Int 29:707–715 DOI: 10.1007/s00198-017-4341-4
Sund R, Honkanen R, Johansson H, Oden A, McCloskey EV, Kanis JA, Kröger H (2014) Evaluation of the FRAX model for the prediction of hip fractures in Kuopio, Finland. Calcif Tiss Int 95:39–45 DOI: 10.1007/s00223-014-9860-9
Grigorie D, Sucaliuc A, Johansson H, Kanis JA, McCloskey E (2013) Incidence of hip fracture in Romania and the development of a Romanian FRAX model. Calcif Tiss Int 92:429–436 DOI: 10.1007/s00223-013-9697-7
Ferrari S, Lippuner K, Lamy O, Meier C (2020) recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Med Wkly 150:w20352. https://doi.org/10.4414/smw.2020.20352
Briot K, Cortet B, Thomas T, Audran M, Blain H, Breuil V, Chapuis L, Chapurlat R, Fardellone P, Feron JM, Gauvain JB, Guggenbuhl P, Kolta S, Lespessailles E, Letombe B, Marcelli C, Orcel P, Seret P, Tremollieres F, Roux C (2012) 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 2012(79):304–313 DOI: 10.1016/j.jbspin.2012.02.014
Abdulla N, Alsaed OS, Lutf A, Alam F, Abdulmomen I, Al Emadi S, Harvey NC, Liu E, Vandenput L, Lorentzon M, McCloskey E, Kanis JA, Johansson H (2022) Epidemiology of hip fracture in Qatar and development of a country specific FRAX model. Arch Osteoporos 17(1):49. 10.1007/s11657-022-01083-z DOI: 10.1007/s11657-022-01083-z
Al-Daghri NM, Sabico S, Al-Saleh Y, Sulimani R, Aljohani NJ, Sheshah E, Alodhayani A, Harvey NC, Liu E, Lorentzon M, McCloskey EV, Vandenput L, Johansson H, Kanis JA (2021) The application of FRAX in Saudi Arabia. Arch Osteoporos 16:166. 10.1007/s11657-021-01024-2 DOI: 10.1007/s11657-021-01024-2
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57
Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster J-Y (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fracture. Osteoporos Int 31:1–12 DOI: 10.1007/s00198-019-05176-3
McClung MR (2021) Role of bone-forming agents in the management of osteoporosis. Aging Clin Exp Res 33:775–791 DOI: 10.1007/s40520-020-01708-8
Curtis EM, Reginster JY, Al-Daghri N, Biver E, Brandi ML, Cavalier E, Hadji P, Halbout P, Harvey NC, Hiligsmann M, Javaid MK, Kanis JA, Kaufman JM, Lamy O, Matijevic R, Perez AD, Radermecker RP, Rosa MM, Thomas T, Thomasius F, Vlaskovska M, Rizzoli R, Cooper C (2022) Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res 34:695–714 DOI: 10.1007/s40520-022-02100-4
Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB (2020) American Association of Cinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26(Suppl 1):1–46 DOI: 10.4158/GL-2020-0524SUPPL
Kanis JA, McCloskey EV, Harvey NC, Johansson H, Leslie WD (2015) Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res 30:1747–1753 DOI: 10.1002/jbmr.2531
Cooney MT, Dudina AL, Graham IM (2009) Value and limitations of existing scores for the assessment of cardiovascular risk. J Am Coll Cardiol 54:1209–1227 DOI: 10.1016/j.jacc.2009.07.020
